Talphera, Inc. Common Stock (TLPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TLPH trades at $0.85 with a market cap of $41.38M and a P/E ratio of -2.37. TLPH moved -1.51% today. Year to date, TLPH is -33.01%; over the trailing twelve months it is +59.81%. Its 52-week range spans $0.38 to $1.57. Analyst consensus is strong buy with an average price target of $3.17. Rallies surfaces TLPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Talphera Advances NEFRO Phase 2 Enrollment, Reports 18% Q1 R&D Spend Rise: In Q1 2026 Talphera advanced its NEFRO Phase 2 trial into dose‐expansion, enrolling its third patient cohort and targeting completion of 60 patients by mid‐year. R&D spending rose 18% to $4.2 million as the company ramps clinical activities, with topline NEFRO data expected in H2 2026.
| Metric | Value |
|---|---|
| Price | $0.85 |
| Market Cap | $41.38M |
| P/E Ratio | -2.37 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.57 |
| 52-Week Low | $0.38 |
| Volume | 1 |
| Avg Volume | 0 |
| Revenue (TTM) | $28.00K |
| Net Income | $-14.29M |
| Gross Margin | 0.00% |
3 analysts cover TLPH: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $3.17.